Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Slice Collision-Induced Unfolding and Molecular Dynamics Reveal How Post-Translational Succination Reshapes SUMO1 Unfolding Pathways.

Journal of the American Society for Mass Spectrometry·2026
Same author

Dialysis disequilibrium syndrome: an underdiagnosed condition? Results from a monocentric observational study.

Clinical kidney journal·2026
Same author

Cholecalciferol and muscle strength in hemodialysis patients: results from the randomized VITADIAL trial.

Clinical kidney journal·2026
Same author

Detection of antibodies against avian influenza in European dairy cattle, the Netherlands, January 2026.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Markerless motion capture methodologies in biomechanics: From 2D images to 3D joint angles, a narrative review.

Gait & posture·2026
Same author

Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships.

European journal of medicinal chemistry·2026
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: May 24, 2025

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System
10:31

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System

Published on: January 13, 2022

9.2K

Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.

Ahd Hamidi1, Marieke Willemsen1, Thomas Robert2

  • 1Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.

Vaccine
|March 4, 2025
PubMed
Summary
This summary is machine-generated.

Regional production of inactivated polio vaccines (IPV) using a novel microfacility enhances vaccine availability. This scalable process improves efficiency and reduces the manufacturing footprint for polio eradication efforts.

Keywords:
Equipment developmentFixed-bed bioreactorInactivated polio vaccineLow cost of goodsSabin attenuated poliovirusTangential flow filtrationVaccinessIPV

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

8.3K
Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System
08:57

Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System

Published on: July 17, 2021

7.2K

Related Experiment Videos

Last Updated: May 24, 2025

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System
10:31

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System

Published on: January 13, 2022

9.2K
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

8.3K
Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System
08:57

Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System

Published on: July 17, 2021

7.2K

Area of Science:

  • Vaccinology
  • Bioprocess Engineering
  • Infectious Disease Control

Background:

  • Polio eradication faces challenges in regions with limited healthcare infrastructure.
  • Ensuring a sustainable and equitable supply of inactivated polio vaccines (IPV) is crucial for the final stages of polio eradication.
  • Existing polio vaccine production methods face limitations due to biosafety requirements and cell line characteristics.

Purpose of the Study:

  • To develop a scalable and efficient regional manufacturing process for inactivated polio vaccines (IPV).
  • To overcome challenges associated with traditional polio vaccine production, including biosafety level 3 containment and Vero cell line adherence.
  • To create a cost-effective solution for regional vaccine production, supporting pandemic preparedness.

Main Methods:

  • Development of an IPV production process utilizing polio Sabin strains within a contained microfacility.
  • Integration of a tangential flow filter (TFF) with a fixed-bed bioreactor (150 m² surface area) to combine production and concentration steps.
  • Implementation of a fully disposable system for virus production, enhancing process efficiency and reducing footprint.

Main Results:

  • Achieved increased process efficiency and a reduced manufacturing footprint through bioreactor and TFF integration.
  • Demonstrated a scalable production process that is demand-driven and utilizes fewer resources.
  • Successfully developed a contained microfacility approach for safe and efficient IPV production.

Conclusions:

  • The developed scalable production process offers a cost-effective method for regional IPV manufacturing.
  • This approach addresses limitations in current polio vaccine production, facilitating equitable access and supply.
  • The technology is suitable for regional demand-driven production and pandemic preparedness efforts.